Editor’s Note: This post by Anny Ortiz is the first in our Pharmaceutical Inequalities series. She explores the existing research landscape of psychedelics and then draws upon her own lived experience of working in a treatment center that offered ibogaine-assisted detoxification to discuss the affordances and unanswered questions of using psychedelics in treatment. The Pharmaceutical Inequalities series is funded by the Holtz Center and the Evjue Foundation.
Today’s post was contributed by Aeden Smith-Ahearn, who once was a heroin addict for almost 7 years. After trying many different traditional methods to get off drugs, he decided to take a chance on Ibogaine treatment for his addiction. Now, 5 years later, Aeden is the treatment coordinator for a major Ibogaine clinic and he has helped hundreds of individuals find a new life through Ibogaine treatment.
When a highly recognized US medical doctor—the one prescribing opiates to patients on a daily basis—walks through the door of an Ibogaine clinic in Mexico to get treatment for his prescription pill addiction, the massive nature of America’s opioid dependence becomes clear—it affects everyone.
It’s not just doctors but lawyers, teachers, students, parents, CEOs, and the list goes on. Everyone, no matter what walk of life, is a target for opiate addiction. It is physically binding, psychologically confining, and, in almost every instance, impossible to break on your own.